No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 248.8x · 10Y median 247.3x · 51st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:06:08.591Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:06:08.591Z. Latest historical point 2022-11-07.
The latest delayed quote for Clene Inc. (CLNN) stock was $3.84 as of Oct 6, 2026, 10:05 AM EDT, down 1.92% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -62.6% · 3-year avg -28.9%/yr · 5-year avg -51.2%/yr
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN).
Biotechnology · Salt Lake City, UT
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.46
Revenue Est.
$70000.00
Last Quarter Results
EPS
$-0.48
vs Estimate
$-0.26
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CLNN | $49.00M | $3.83 | -1.92% | -62.62% | -51.16% | N/A | N/A |
| 2CELU | $49.06M | $1.70 | -0.88% | -19.63% | -52.57% | N/A | vs CLNN |
| 3COCH | $50.95M | $0.66 | +1.38% | -19.94% | -41.73% | N/A | vs CLNN |
| 4LITS | $46.96M | $1.38 | -1.42% | -45.15% | N/A | N/A | vs CLNN |
| 5MBOT | $51.06M | $1.12 | +4.72% | -64.98% | -31.63% | -39.57% | vs CLNN |
| 6INMB | $51.31M | $1.93 | -0.52% | -6.70% | -36.88% | N/A | vs CLNN |
N/A
$90000.00
vs Estimate
$61000.00
Consensus Rating
Based on 5 analysts
Average Price Target
$32.20
+739.6% upside
Low
$20.00
Current
$3.83
High
$50.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.47 | $-0.45 | $-0.42 | 2 |
| Quarter ending Dec 2026 | $-0.42 | $-0.27 | $-0.13 | 2 |
| Quarter ending Mar 2027 | $-1.13 | $-0.66 | $-0.19 | 1 |
| Quarter ending Jun 2027 | $-1.44 | $-0.84 | $-0.25 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.56 | $-1.08 | $0.40 | 3 |
| FY 2027 | $-1.79 | $-1.50 | $-1.19 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $38888.00 | $70000.00 | $101111.00 | 3 |
| Quarter ending Dec 2026 | $36363.00 | $80000.00 | $123636.00 | 3 |
| Quarter ending Mar 2027 | $22727.00 | $50000.00 | $77272.00 | 1 |
| Quarter ending Jun 2027 | $22727.00 | $50000.00 | $77272.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $187137.00 | $276250.00 | $356451.00 | 4 |
| FY 2027 | $1.19M | $26.40M | $51.61M | 4 |
